colorectal-cancer

A next-generation fluoropyrimidine beats 5-FU in resistant colorectal cancer with lower toxicity

5-FU (fluorouracil) is still the backbone of colorectal cancer chemotherapy, but resistance is common and side effects are severe. This study introduces CF10, a polymeric version of a fluoropyrimidine designed to deliver the active drug (FdUMP) more sustainably and with a better safety profile.

In 5-FU-refractory cell and animal models, CF10 demonstrated superior anti-tumor activity compared to standard 5-FU while maintaining — and in some models improving — the therapeutic index (the gap between effective dose and toxic dose). This suggests CF10 could offer a genuine clinical advance for patients who have failed standard fluoropyrimidine therapy.

Colorectal cancer is one of the most common cancers worldwide, so improvements to fluoropyrimidine efficacy could have large population-level impact.

Key Findings

CF10, a novel polymeric fluoropyrimidine, shows superior efficacy in 5-FU-resistant colorectal cancer models
CF10 provides sustained FdUMP delivery compared to bolus 5-FU administration
Improved therapeutic index observed compared to standard 5-FU
Active in 5-FU-refractory preclinical models
Favorable safety profile maintained at therapeutic doses

Implications

If CF10's preclinical superiority translates to humans, it could address a major unmet need: effective second-line chemotherapy for 5-FU-resistant colorectal cancer. The polymer delivery approach may also be applicable to other fluoropyrimidine-treated cancers including gastric and pancreatic cancer.

Caveats

Preprint — not peer reviewed. Based on abstract only; full efficacy and safety data not reviewed. Preclinical only — no human data. 5-FU-refractory models may not fully replicate clinical resistance mechanisms. Requires full trial program before clinical use.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.